Literature DB >> 29694242

Endostar, a Modified Endostatin Induces Vascular Normalization to Improve Chemotherapy Efficacy Through Suppression of Src Signaling Pathway.

Min Yu1, Yao Han2, Hongyu Zhuo3, Shuang Zhang4.   

Abstract

Pathological angiogenesis can be a significant barrier to effective cancer therapy. Recent evidence suggests that Endostar may induce vascular normalization, thereby improving tumor perfusion and systemic chemotherapy. However, the molecular mechanism by which Endostar makes chemotherapy more effective remains to be fully elucidated. In this study, established 4T1 breast tumor-bearing animals treated with Endostar were evaluated at serial time points for treatment-associated changes in vascular architecture. As a result, Endostar induced a morphologically and functionally normalized vascular network. Combined Endostar and doxorubicin exhibited significant antitumor (34% of control size) and antimetastatic effects (29% of control metastatic nodules) in vivo. Finally, a two-dimensional gel electrophoresis and MALDIQ-TOF MS/MS-based proteomics approach was used to identify differentially expressed proteins involved in vascular normalization during Endostar administration. SRCIN1 was detected as one of the most significantly increased proteins. SRCIN1 is a novel Src-binding protein that regulates Src activation through C-terminal Src kinase, and attenuated Src activation during Endostar treatment was further confirmed by immunoblotting. Collectively, these data provided a molecular basis for vascular normalization, which were associated with the observed synergistic effect in vivo.

Entities:  

Keywords:  Endostar; SRCIN1; angiogenesis; breast cancer; vascular normalization

Mesh:

Substances:

Year:  2018        PMID: 29694242     DOI: 10.1089/cbr.2017.2399

Source DB:  PubMed          Journal:  Cancer Biother Radiopharm        ISSN: 1084-9785            Impact factor:   3.099


  6 in total

1.  Endostar Plus Apatinib Successfully Achieved Long Term Progression-Free Survival in Refractory Ovarian Cancer: A Case Report and Literature Review.

Authors:  Chunmei Xiao; Fangye Xu; Rong Wang; Qi Liang; Kai Shen; Jiali Xu; Lianke Liu
Journal:  Onco Targets Ther       Date:  2021-12-01       Impact factor: 4.147

2.  Comparison of Endostar continuous versus intermittent intravenous infusion in combination with first-line chemotherapy in patients with advanced non-small cell lung cancer.

Authors:  Yuan Cheng; Ligong Nie; Ying Liu; Zhe Jin; Xi Wang; Zhanwei Hu
Journal:  Thorac Cancer       Date:  2019-06-03       Impact factor: 3.500

3.  Experimental study of the vascular normalization window for tumors treated with apatinib and the efficacy of sequential chemotherapy with apatinib in lung cancer-bearing mice and patients.

Authors:  Mingtao Liu; Hui Li; Xiuxiu Wang; Lijun Jing; Peng Jiang; Yu Li
Journal:  Cancer Med       Date:  2020-02-19       Impact factor: 4.452

4.  Endostatin Genetically Engineered Placental Mesenchymal Stromal Cells Carrying Doxorubicin-Loaded Mesoporous Silica Nanoparticles for Combined Chemo- and Antiangiogenic Therapy.

Authors:  Paz de la Torre; Juan L Paris; Miguel Fernández-de la Torre; María Vallet-Regí; Ana I Flores
Journal:  Pharmaceutics       Date:  2021-02-10       Impact factor: 6.321

5.  The Efficacy and Safety of Continuous Intravenous Endostar Treatment Combined With Concurrent Chemoradiotherapy in Patients With Locally Advanced Cervical Squamous Cell Carcinoma: A Randomized Controlled Trial.

Authors:  Hang Shu; Yaqin Dong; Zhonghua Xu; Weiwei Luo; Lei Xu; Haochen Zhu; Linghui Cheng; Yin Lv
Journal:  Front Oncol       Date:  2021-08-13       Impact factor: 6.244

6.  Continuous intravenous infusion of recombinant human endostatin using infusion pump plus chemotherapy in non-small cell lung cancer.

Authors:  Zhi-Quan Qin; Si-Fu Yang; Yun Chen; Chao-Jin Hong; Tong-Wei Zhao; Guo-Rong Yuan; Liu Yang; Liang Gao; Xiao Wang; Li-Qin Lu
Journal:  World J Clin Cases       Date:  2022-02-06       Impact factor: 1.337

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.